• Ambu’s EBIT jumped 99% to DKK 293 million in Q4 2025/26.
• Revenue rose 16% to DKK 1.7 billion, while free cash flow before acquisitions climbed 66% to DKK 216 million.
• The acquisition of TIMS Medical expanded its endoscopy offering with hospital integration and workflow technology.
• For 2026/27, Ambu expects organic revenue growth of 9.5–11.5% and an EBIT margin of 13–15%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ambu A/S published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.